Organization | Hrain Biotechnology Co., Ltd.

Hrain Biotechnology Co., Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Shanghai China (2015)

Organization Overview

First Clinical Trial

2018

NCT04303520

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Hrain Biotechnology | Hrain Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

cd19 car-t cells (7 trials)

Drugs in Phase 1 Trials (9)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

bcma car-nk cells (1 trial)

bcma-pd1-cart cell (1 trial)

cd22 car-t cells (2 trials)

ciltacabtagene autoleucel (Carvykti) (3 trials)

cyclophosphamide (cytoxan) (6 trials)

fludarabine (fludara) (6 trials)

human cd19 targeted dash car-t cells (1 trial)

mesothelin car t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Ovarian Epithelial (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Ovarian Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Syndrome (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 14
# of Trial APIs: 10